Back

Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor - Chimeric Antigen Receptor T cell Interactions

Nguyen, D. T.; Liu, R.; Ogando-Rivas, E.; Pepe, A.; Pedro, D.; Qdaisat, S.; Nguyen, T. Y. N.; Lavrador, J.; Golde, G.; Smolcheck, R.; Ligon, J.; Jin, L.; Tao, H.; Webber, A.; Phillpot, S.; Mitchell, D.; Sayour, E. J.; Huang, J.; Castillo, P.; Sawyer, W. G.

2023-02-21 bioengineering
10.1101/2023.02.17.529033 bioRxiv
Show abstract

Cancer immunotherapy offers lifesaving treatments for cancers, but the lack of reliable preclinical models that could enable the mechanistic studies of tumor-immune interactions hampers the identification of new therapeutic strategies. We hypothesized 3D confined microchannels, formed by interstitial space between bio-conjugated liquid-like solids (LLS), enable CAR T dynamic locomotion within an immunosuppressive TME to carry out anti-tumor function. Murine CD70-specific CAR T cells cocultured with the CD70-expressing glioblastoma and osteosarcoma demonstrated efficient trafficking, infiltration, and killing of cancer cells. The anti-tumor activity was clearly captured via longterm in situ imaging and supported by upregulation of cytokines and chemokines including IFNg, CXCL9, CXCL10, CCL2, CCL3, and CCL4. Interestingly, target cancer cells, upon an immune attack, initiated an "immune escape" response by frantically invading the surrounding microenvironment. This phenomenon however was not observed for the wild-type tumor samples which remained intact and produced no relevant cytokine response. Single cells collection and transcriptomic profiling of CAR T cells at regions of interest revealed feasibility of identifying differential gene expression amongst the immune subpopulations. Complimentary 3D in vitro platforms are necessary to uncover cancer immune biology mechanisms, as emphasized by the significant roles of the TME and its heterogeneity.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
APL Bioengineering
19 papers in training set
Top 0.1%
7.3%
2
Advanced Science
286 papers in training set
Top 1%
5.5%
3
Advanced Healthcare Materials
85 papers in training set
Top 0.4%
5.5%
4
Theranostics
37 papers in training set
Top 0.1%
4.9%
5
Integrative Biology
14 papers in training set
Top 0.1%
4.3%
6
npj Precision Oncology
53 papers in training set
Top 0.3%
4.3%
7
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.6%
4.3%
8
Biomaterials
84 papers in training set
Top 0.5%
3.4%
9
Bioengineering & Translational Medicine
21 papers in training set
Top 0.1%
3.2%
10
Science Advances
1243 papers in training set
Top 10%
3.2%
11
Nature Communications
5641 papers in training set
Top 38%
2.7%
12
iScience
1154 papers in training set
Top 11%
2.4%
50% of probability mass above
13
Neuro-Oncology Advances
25 papers in training set
Top 0.2%
2.4%
14
Advanced Therapeutics
17 papers in training set
Top 0.1%
2.4%
15
Scientific Reports
3612 papers in training set
Top 43%
2.4%
16
PLOS ONE
5266 papers in training set
Top 46%
1.9%
17
ACS Nano
113 papers in training set
Top 1%
1.9%
18
Molecular Therapy
81 papers in training set
Top 0.9%
1.7%
19
eLife
5828 papers in training set
Top 48%
1.7%
20
Cellular and Molecular Bioengineering
22 papers in training set
Top 0.3%
1.3%
21
Frontiers in Oncology
103 papers in training set
Top 3%
1.1%
22
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 2%
1.1%
23
Antibody Therapeutics
16 papers in training set
Top 0.2%
1.0%
24
Cells
249 papers in training set
Top 5%
1.0%
25
Small Methods
29 papers in training set
Top 0.5%
1.0%
26
Communications Biology
993 papers in training set
Top 26%
1.0%
27
Lab on a Chip
96 papers in training set
Top 0.9%
1.0%
28
Small
78 papers in training set
Top 2%
0.8%
29
Journal of Biological Engineering
12 papers in training set
Top 0.1%
0.8%
30
Journal of Controlled Release
44 papers in training set
Top 0.7%
0.8%